12 Results for "

HiBiT

" in MedChemExpress (MCE) Product Catalog:
Products (12)

12 Results for "HiBiT" in MCE Product Catalog:

1
1 Cited Publications
Cat. No.: HY-160528
Research Areas:  

Cancer

IBG3 is a Molecular glue degrader targeting BRD2 and BRD4, with DC50 values of 8.6 pM and 6.7 pM, respectively. IBG3 binds simultaneously to the tandem bromodomains of BRD2/BRD4, induces intramolecular conformational changes, enhances the affinity of BRD2/BRD4 for DCAF16, and promotes ubiquitination and degradation. IBG3 is applicable to the research of chronic myeloid leukemia .
Cat. No.: HY-173066
CAS No.: 3048196-52-4
Research Areas:  

Cancer

NU227326 is a blood-brain barrier penetrant IDO1 PROTAC degrader, with a DC50 of 4.5 nM in HiBiT degradation assays. NU227326 degrades IDO1 in U87 and GBM43 cells, with DC50 values of 7.1 nM and 11.8 nM, respectively (WB assays). NU227326 is applicable to research related to glioblastoma, prostate cancer, triple-negative breast cancer, pancreatic cancer, and ovarian cancer .
Cat. No.: HY-169370
CAS No.: 2767166-30-1
Target:  

STAT

STAT3 HiBiT degrader 1 is a STAT3 HiBiT degrader with a DC50 of less than 0.05 μM in A549 cells .
Cat. No.: HY-179233
CAS No.: 3105288-31-8
Target:  

PROTACs STAT

Research Areas:  

Cancer

PROTAC STAT6 degrader-2 is a highly efficient PROTAC degrader targeting STAT6. PROTAC STAT6 degrader-2 has a DC50 value of 1-10 nM for STAT6 in human PBMC cells and a DC50 value of less than 100 nM for STAT6 in HEK293-HIBiT-STAT6 cells. PROTAC STAT6 degrader-2 can be used for STAT6-mediated diseases .
Cat. No.: HY-173327
CAS No.: 3055207-38-7
Research Areas:  

Cancer

BRD4 degrader-6 is a dimeric BDR4 PROTAC degrader (DC50: < 0.1 μM). BRD4 degrader-6 promotes the ubiquitination and degradation of BDR4 and has anticancer activity .
Cat. No.: HY-P11157
CAS No.: 1628913-96-1
Target:  

HIV

Research Areas:  

Infection

DrkBiT is a membrane-impermeable peptide competing with HiBiT. DrkBiT binds to LgBiT. DrkBiT can be used in the research of HIV-1 infection .
Cat. No.: HY-W1128213
CAS No.: 2983841-00-3
Research Areas:  

Inflammation/Immunology Cancer

IKZF2-degrader 2 is a selective and orally active IKZF2 molecular glue degrader with DC50 values of 0.5 nM and 1.8 nM in HiBit and FACS. The IKZF2-degrader 2 mediates the ubiquitination and degradation of target proteins by recruiting the CRL4-CRBN E3 ubiquitin ligase. IKZF2-degrader 2 displays moderate degradation against SALL4 with a DC50 of 9 nM but does not induce any significant degradation towards IKZF1, IKZF3, CK1α and GSPT1. IKZF2-degrader 2 can be used for the study of cancer immunology .
Cat. No.: HY-168236
CAS No.: 2641510-88-3
Target:  

PROTACs SWI/SNF Complex

Research Areas:  

Cancer

PROTAC SMARCA2 degrader-28 (Compound 158) is a PROTAC degrader for SMARCA2, that degrades SMARCA2 with a DC50 of 3 nM in HiBiT A549 cells .
Cat. No.: HY-137089
CAS No.: 1249-84-9
Synonyms: 20.25-Diazacholesterol dihydrochloride
Target:  

CETP

Research Areas:  

Endocrinology

Azacosterol (SC-12937) dihydrochloride is a chemosterilant which in-hibits reproduction in the pigeon. Azacosterol (SC-12937) dihydrochloride exerts its inhibitory effect through the blocking of the synthesis of cholesterol, thought to be a vital component in the formation of egg yolks .
Cat. No.: HY-156526
CAS No.: 2924182-31-8
Research Areas:  

Others

PHD-IN-1 (compound 80) is a potent inhibitor of PHD2,with an IC50 value of ≤5 nM. PHD-IN-1 shows EC50s of 2.5 μM in EPO Elisa assay both in Caco2-HIFla-HiBiT-clone-1 cells and Hep3B cells,respectively .
Cat. No.: HY-169264
Research Areas:  

Cancer

SJYHJ-026 (compound 37) is a pregnane X receptor (PXR) PROTAC degrader with the DC50 of 86.6 nM and maximal degradation of 66.4%. SJYHJ-026 shows cell cytotoxic aganist SNU-C4 HiBiT-PXR KI cells with the IC50 values of 97.4 μM (24 h) and 99.5 μM (72 h) .
Cat. No.: HY-184335
CAS No.: 3097564-20-7
Research Areas:  

Cancer

PROTAC BET Degrader-18 is a PROTAC targeting BET, with a DC50 of 0.676 nM in HEK293-BRD4-HiBiT-KI cells. PROTAC BET Degrader-18 mainly targets and degrades BRD4 (EC50 = 59.91 nM), and exhibits weak degradation activity against BRD2. PROTAC BET Degrader-18 inhibits the expression of downstream oncoprotein c-Myc, thereby inducing cell cycle arrest and apoptosis, while suppressing oncoprotein expression. PROTAC BET Degrader-18 shows antiproliferative activity against acute myeloid leukemia cells and triple-negative breast cancer cells. PROTAC BET Degrader-18 demonstrates antitumor efficacy in xenograft mouse models. PROTAC BET Degrader-18 can be used for the research of acute myeloid leukemia and triple-negative breast cancer .
  • 1